INFLUENZA VACCINES - A MAIN PROBLEM IN CONTROL OF PANDEMICS

The optimal strategy for control of pandemic influenza is early vaccin ation with influenza vaccine produced from influenza pandemic strains. However, for pandemic control, vaccine improvements are essential and should include quicker ways of manufacturing and testing of vaccine a s well as flexibility on the part of licensing bodies. The production of mass doses of monovalent vaccine in a short time can be more realis tic if egg independent production technology can be adopted. In this r espect production of an influenza vaccine on a stable cell line can so lve many of the problems in increased production of influenza vaccine. But the difficulty with influenza vaccines is that the yield of human influenza viruses on tissue culture is much lower than in embryonated eggs. A new high-yield donor is needed for construction of recombinan ts with a new pandemic strain, which can replicate in a stable cell li ne with high titre. The live influenza vaccine may be the most appropr iate for prophylaxis of influenza pandemic, as the implementation of t his vaccine for mass vaccination is simpler than of inactivated influe nza vaccine, and this vaccine, after one immunization of unprime perso ns, induces local mucocosa immunity which plays an important role in t he protection against influenza.